Theravance Biopharma (TBPH) Q1 Loss Narrows, Sales Up Y/Y
Zacks Investment Research | May 08, 2018 11:03PM ET
Theravance Biopharma (NASDAQ:TBPH) reported first-quarter 2018 loss of $1.22 per share, narrower than the Zacks Consensus Estimate of a loss of $1.29 and the year-ago loss of $1.27.
Total revenues in the quarter surged 169.5% year over year to $8.3 million. This upside can mainly be attributed to amortization of the upfront fees related to a global development and commercialization agreement with Janssen, subsidiary of Johnson & Johnson (NYSE:JNJ) , for TD-1473. Moreover, the top line surpassed the Zacks Consensus Estimate of $5.74 million.
Theravance shares were up 3.4% on May 8, following the earnings release. However, shares have underperformed the industry in a year’s time. The stock has lost 12.6% compared with the industry’s 2.9% decrease.
Quarterly Details
Vibativ generated U.S. revenues of $3.7 million in the first quarter, up 20.6% from the year-ago period. Revenues from collaborations were $4.6 million compared with $37,000 in the year-earlier quarter.
Research and development expenses were $47.8 million, up 21.4% from the year-ago period while selling, general & administrative expenses rose 44.6% to $24.7 million. The increase in expenses was due to higher employee-related costs and stock-based compensation.
Pipeline and Other Updates
In February 2018, Theravance entered into a global collaboration agreement with Janssen to jointly develop and commercialize its pan-Janus kinase inhibitor, TD-1473, for the treatment of inflammatory intestinal diseases. A phase II study and a phase IIb/III study are likely to be initiated in the second half of 2018 to evaluate TD-1473 in Crohn's disease and ulcerative colitis, respectively.
In January, Theravance along with partner Mylan (NASDAQ:MYL) announced that the new drug application ("NDA") for pipeline candidate, revefenacin (TD-4208), has been accepted by the FDA for treatment of adults with chronic obstructive pulmonary disease. A response from the regulatory body is expected on Nov 13, 2018. The company is preparing for the commercial launch of the drug upon potential approval.
The company’s collaboration partner Alfasigma for velusetrag (TD-5108) opted-in to acquire rights to the candidate. Per the opt-in decision, global rights to develop, manufacture and commercialize velusetrag will be transferred to Alfasigma for $10 million upfront fees and future milestone payments and royalties. Theravance has decided not to pursue further development of velusetrag as part of its pipeline strategy.
2018 Outlook Reiterated
Theravance continues to expect operating loss, excluding non-cash share-based compensation, for 2018 in the range of $180-$200 million.
Get The News You Want
Theravance Biopharma, Inc. Price, Consensus and EPS Surprise
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.